相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Somatic activating ARAF mutations in Langerhans cell histiocytosis
David S. Nelson et al.
BLOOD (2014)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
Marcin Imielinski et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Matteo S. Carlino et al.
MOLECULAR ONCOLOGY (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
Inhibition of mutant BRAF splice variant signaling by next- generation, selective RAF inhibitors
Kevin J. Basile et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Luping Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Anna A. Marusiak et al.
NATURE COMMUNICATIONS (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies
Omar Abdel-Wahab et al.
CANCER DISCOVERY (2014)
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
Julien Haroche et al.
BLOOD (2013)
RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
Matthew Holderfield et al.
CANCER CELL (2013)
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Akito Nakamura et al.
CANCER RESEARCH (2013)
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii et al.
CANCER RESEARCH (2013)
Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Jiancheng Hu et al.
CELL (2013)
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2013)
Resistance to BRAF-targeted therapy in melanoma
Ryan J. Sullivan et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
Matteo S. Carlino et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization
Hugo Lavoie et al.
NATURE CHEMICAL BIOLOGY (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction
Fumi Shima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Elucidating Distinct Roles for NF1 in Melanomagenesis
Ophelia Maertens et al.
CANCER DISCOVERY (2013)
Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Amy Young et al.
CANCER DISCOVERY (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
Qi Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
MEK1/2 dual-specificity protein kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche et al.
BLOOD (2012)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Suzanne Leijen et al.
CLINICAL CANCER RESEARCH (2012)
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Maria Martinez-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
Michael Roering et al.
EMBO JOURNAL (2012)
Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated RAF1 Mutants
Xue Wu et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Margaret K. Callahan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions
Edna F. Choo et al.
DRUG METABOLISM AND DISPOSITION (2012)
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Qing Dong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Inhibition of Ras for cancer treatment: the search continues
Antonio T. Baines et al.
FUTURE MEDICINAL CHEMISTRY (2011)
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Emma R. Cantwell-Dorris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
Raphaela Fritsche-Guenther et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recurrent BRAF mutations in Langerhans cell histiocytosis
Gayane Badalian-Very et al.
BLOOD (2010)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kihyun Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Eric B. Haura et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting the RAF-MEK-ERK pathway in cancer therapy
Clara Montagut et al.
CANCER LETTERS (2009)
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Cory Iverson et al.
CANCER RESEARCH (2009)
MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas
Avaniyapuram Kannan Murugan et al.
CELL CYCLE (2009)
Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control
Alex M. Aronov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E
Florian A. Karreth et al.
MOLECULAR CELL (2009)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma
Jenifer L. Marks et al.
CANCER RESEARCH (2008)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting RAS and PI3K in lung cancer
Julian Downward
NATURE MEDICINE (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
V Emuss et al.
CANCER RESEARCH (2005)
Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex
M Ohori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Raf-1 regulates Rho signaling and cell migration
K Ehrenreiter et al.
JOURNAL OF CELL BIOLOGY (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Rote of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1
E O'Neill et al.
SCIENCE (2004)
MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors
JS Sebolt-Leopold
CURRENT PHARMACEUTICAL DESIGN (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
